138 related articles for article (PubMed ID: 10782917)
1. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
Mitsuda A; Suou T; Ikuta Y; Kawasaki H
J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
3. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
4. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
5. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
Leroy V; De Traversay C; Barnoud R; Hartmann JD; Baud M; Ouzan D; Zarski JP
J Hepatol; 2001 Jul; 35(1):120-6. PubMed ID: 11495029
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Nøjgaard C; Johansen JS; Krarup HB; Holten-Andersen M; Møller A; Bendtsen F;
Scand J Gastroenterol; 2003 Jun; 38(6):659-65. PubMed ID: 12825876
[TBL] [Abstract][Full Text] [Related]
7. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
[TBL] [Abstract][Full Text] [Related]
8. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
9. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
[TBL] [Abstract][Full Text] [Related]
10. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
Suou T; Hosho K; Kishimoto Y; Horie Y; Kawasaki H
Hepatology; 1995 Aug; 22(2):426-31. PubMed ID: 7635409
[TBL] [Abstract][Full Text] [Related]
11. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
12. Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.
Lebensztejn DM; Sobaniec-Lotowska ME; Kaczmarski M; Voelker M; Schuppan D
World J Gastroenterol; 2006 Jun; 12(21):3338-43. PubMed ID: 16733849
[TBL] [Abstract][Full Text] [Related]
13. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.
Flisiak R; Jaroszewicz J; Lapinski TW; Flisiak I; Prokopowiczi D
World J Gastroenterol; 2005 Nov; 11(43):6833-8. PubMed ID: 16425392
[TBL] [Abstract][Full Text] [Related]
14. Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon.
Gallorini A; Plebani M; Pontisso P; Chemello L; Masiero M; Mantovani G; Alberti A
Liver; 1994 Oct; 14(5):257-64. PubMed ID: 7997085
[TBL] [Abstract][Full Text] [Related]
15. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection.
Valva P; Casciato P; Diaz Carrasco JM; Gadano A; Galdame O; Galoppo MC; Mullen E; De Matteo E; Preciado MV
PLoS One; 2011; 6(8):e23218. PubMed ID: 21858035
[TBL] [Abstract][Full Text] [Related]
16. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values.
Lichtinghagen R; Pietsch D; Bantel H; Manns MP; Brand K; Bahr MJ
J Hepatol; 2013 Aug; 59(2):236-42. PubMed ID: 23523583
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features.
Serejo F; Emerit I; Filipe PM; Fernandes AC; Costa MA; Freitas JP; de Moura MC
Can J Gastroenterol; 2003 Nov; 17(11):644-50. PubMed ID: 14631465
[TBL] [Abstract][Full Text] [Related]
18. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
[TBL] [Abstract][Full Text] [Related]
19. [Serum aminoterminal peptide of type III procollagen (PIIINP) and transforming growth factor-beta1 (TGF-beta1) levels in patients with chronic hepatitis B and C].
Marek B; Kajdaniuk D; Janczewska-Kazek E; Beniowski M; Swietochowska E; Kos-Kudła B; Ostrowska Z; Mazurek U; Wilczok T; Nowak M; Siemińska L; Borgiel-Marek H; Strzyzewski A; Januła A; Sierek K; Niedzielski Z
Pol Arch Med Wewn; 2003 Jun; 109(6):603-8. PubMed ID: 14567092
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis.
Lidbury JA; Hoffmann AR; Fry JK; Suchodolski JS; Steiner JM
Can J Vet Res; 2016 Oct; 80(4):302-308. PubMed ID: 27733785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
